Last reviewed · How we verify
A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma
This study will look how using taken from your tumors and mixed with special immune stimulating cells from another person's blood in given back to you in a series "fusion cell" injections, will effect your body. The primary goal of the study is to see if giving the experimental fusion cell injections is safe. We will also be looking to see what effect the experimental treatment as on your immune system and whether it has an effect on your cancer.
Details
| Lead sponsor | Beth Israel Deaconess Medical Center |
|---|---|
| Phase | Phase 1/Phase 2 |
| Status | COMPLETED |
| Enrolment | 40 |
| Start date | 2002-12 |
| Completion | 2008-02 |
Conditions
- Renal Cell Carcinoma
Interventions
- Electrofusion DC vaccine
Primary outcomes
- To assess the safety of 3 serial vaccinations with allogeneic DCs: autologous tumor-derived cells subjected to electrofusion in patients with AJCC stage IV RCC — screening/baseline, treatment period, follow-up and long-term follow-up
Countries
United States